Methamphetamine Addiction: A Growing Crisis and Challenges in Treatment

Introduction

While the opioid epidemic and fentanyl overdoses have dominated the public health discourse, methamphetamine use has been quietly rising. Often overshadowed by opioids, methamphetamine poses significant dangers, particularly in the growing trend of dual methamphetamine and fentanyl use. According to data from the Centers for Disease Control and Prevention’s State Unintentional Drug Overdose Reporting System (SUDORS), many overdose deaths in 2022 involved both opioids and stimulants, highlighting the interconnected nature of these drug crises.¹

Sam Quinones, in The Least of Us, attributes the resurgence of methamphetamine use to its affordability and widespread availability.² Most methamphetamine is produced in Mexico on an industrial scale and smuggled into the U.S., leading to its easy accessibility nationwide. This accessibility, combined with its powerful effects, has made methamphetamine a significant contributor to the addiction landscape.

Health Consequences

Unlike opioid overdoses, which often result in fatal outcomes, methamphetamine use leads to long-term deterioration in both physical and mental health. Users experience a wide array of severe complications, including:

• Cardiovascular events, such as myocardial infarction and heart failure
• Dental decay, commonly known as “meth mouth”
• Muscle wasting or rhabdomyolysis
• Cerebral vasculitis and hemorrhagic strokes
• Psychosis (auditory and visual hallucinations, delusions)
• Mania
• Cognitive impairment
• Parkinson’s Disease

Current Psychosocial Interventions and Limitations

Currently, no FDA-approved pharmacologic treatments exist for methamphetamine use disorder. As a result, treatment is primarily based on psychosocial interventions, including cognitive-behavioral therapy (CBT), a cornerstone of addiction treatment that helps users identify and change harmful thought patterns and behaviors. 12-step programs, modeled after Alcoholics Anonymous, provide peer support for individuals seeking recovery from substance use.

However, these interventions face significant challenges. Approximately 60% of users relapse within one year, highlighting the difficulty of sustaining long-term recovery. Moreover, many individuals lack access to intensive therapies like CBT due to socioeconomic barriers, limited availability of specialized services, or the inability to engage in consistent treatment. This creates a treatment gap, especially in underserved communities, where methamphetamine use is often prevalent.

Off-Label Pharmacological Approaches

Researchers have investigated several pharmacologic agents off-label to treat methamphetamine use disorder. Studies have shown that mirtazapine provides moderate efficacy at a dose of 30 mg for methamphetamine users who identify as men who have sex with men (MSM).³ Another study demonstrated modest success using a combination of bupropion and the opioid antagonist naltrexone in medication-assisted therapy.⁴ Researchers have also explored “stimulant replacement therapy,” similar to opioid medication-assisted therapy, using prescription stimulants like methylphenidate (Ritalin) and amphetamine (Adderall).⁵ Preliminary findings suggest that methamphetamine users with comorbid attention-deficit/hyperactivity disorder (ADHD) may benefit from treatment with methylphenidate, although these studies involved higher-than-normal therapeutic doses and small sample sizes.

Despite promising preliminary findings, large-scale clinical trials for methamphetamine treatments face significant barriers. Many of the drugs being investigated, such as mirtazapine, are off-patent, meaning pharmaceutical companies have little financial incentive to fund costly trials. As a result, much of the research into methamphetamine treatment is investigator-initiated rather than industry-sponsored, leading to smaller sample sizes and less rigorous study designs.

Furthermore, the complexity of stimulant addiction poses additional challenges for clinical research. Methamphetamine affects the brain’s reward pathways differently than opioids, making it harder to develop medications that specifically target its addictive effects. Without substantial investment in research, the development of FDA-approved treatments for methamphetamine use disorder remains unlikely in the near future.

Innovative Approaches to Treatment and Future Directions

Despite these obstacles, there are ongoing efforts to explore novel treatment approaches for methamphetamine addiction. Among the most innovative are:

• Vaccines: Researchers have developed vaccines aimed at blocking the rewarding effects of cocaine, which could provide valuable insights for developing similar treatments for methamphetamine.⁶ These vaccines work by stimulating the immune system to produce antibodies that neutralize the drug before it can enter the brain, thereby reducing its euphoric effects.
• Deep Brain Stimulation (DBS): Although highly invasive, DBS has shown promise as a treatment for drug addiction, including methamphetamine.⁷ By targeting specific areas of the brain involved in reward and impulse control, DBS could potentially reduce cravings and improve self-regulation in individuals with severe addiction.

Both of these approaches are still in the experimental stages, but they represent exciting possibilities for the future of methamphetamine treatment. Continued research and investment are essential to advancing these novel therapies and addressing the methamphetamine crisis.

Conclusion

Methamphetamine addiction presents a complex and growing challenge. As methamphetamine use continues to rise, so too do the health consequences, relapse rates, and societal costs. While psychosocial interventions remain the primary treatment option, emerging pharmacologic approaches offer hope for more effective therapies. However, significant barriers remain in developing FDA-approved treatments, including financial disincentives and the unique neurobiology of stimulant addiction.

Addressing the methamphetamine crisis will require a comprehensive approach that includes continued research, investment in novel treatments, and expanded access to psychosocial interventions. Only by combining these efforts can we hope to mitigate the growing impact of methamphetamine addiction.

References

1. Centers for Disease Control and Prevention. State Unintentional Drug Overdose Reporting System (SUDORS). 2022. Available at: https://www.cdc.gov/overdose-prevention/data-research/facts-stats/sudors-dashboard-fatal-overdose-data.html. Accessed July 10, 2024.
2. Quinones S. The Least of Us: True Tales of America and Hope in the Time of Fentanyl and Meth. New York, NY: Bloomsbury Publishing; 2021.
3. Centers for Disease Control and Prevention. State Unintentional Drug Overdose Reporting System (SUDORS). 2022. Available at: https://www.cdc.gov/overdose-prevention/data-research/facts-stats/sudors-dashboard-fatal-overdose-data.html. Accessed July 10, 2024.
4. Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168-1175.
5. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140-153.
6. Mak A, Bested A. Role of stimulant replacement therapy in methamphetamine addiction. Can Fam Physician. 2022;68(5):327-328.
7. Orson FM, Kinsey BM, Singh RA, et al. Cocaine vaccine dAd5GNE protects against moderate daily and high-dose “binge” cocaine use. Vaccine. 2020;38(4):736-744.
8. Han J, Zhang J, Chen H, et al. Deep brain stimulation for drug addiction: a review of human evidence and potential mechanisms. Front Hum Neurosci. 2017;11:1-13.